Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.74 |
| ▸ | KDR | P35968 | 1/20 | 0.74 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.74 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.74 |
| ▸ | CDK4 | P11802 | 1/20 | 0.74 |
| ▸ | CDK9 | P50750 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31187476 | 1.00 | SRPK1 (0.74) | SRPK1KDRSRPK2SRPK3CDK4 | |
| SCHEMBL22700680 | 1.00 | SRPK1 (0.74) | SRPK1KDRSRPK2SRPK3CDK4 | |
| SCHEMBL20198520 | 0.87 | NPSR1 (0.72) | SRPK1KDRSRPK2SRPK3CDK4 | |
| SCHEMBL16697303 | 0.86 | MAPT (0.64) | SRPK1KDRSRPK2SRPK3CDK4 | |
| SCHEMBL1110476 | 0.85 | SRPK1 (1.00) | SRPK1KDRSRPK2SRPK3MAPT | |
| SCHEMBL1110544 | 0.85 | SRPK1 (1.00) | SRPK1KDRSRPK2SRPK3MAPT | |
| SCHEMBL3485927 | 0.85 | SRPK1 (1.00) | SRPK1KDRSRPK2SRPK3MAPT | |
| SCHEMBL3485238 | 0.85 | KDR (0.71) | SRPK1KDRSRPK2SRPK3CDK4 | |
| SCHEMBL3485243 | 0.85 | KDR (0.71) | SRPK1KDRSRPK2SRPK3CDK4 | |
| SCHEMBL23196029 | 0.85 | CDK4 (0.74) | SRPK1KDRSRPK2SRPK3CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210100781-A1 | TUMOR SUPPRESSION | KYOTO UNIVERSITY (JP) | 2021-04-08 | — | — | US | disclosed |
| WO-2020235672-A1 | PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE | 国立大学法人京都大学 (JP) | 2020-11-26 | — | — | WO | disclosed |
| EP-2666481-B9 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA MASATOSHI (JP) | 2019-05-22 | — | — | EP | disclosed |
| EP-2666481-B1 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA MASATOSHI (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-1712242-B1 | METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT | HAGIWARA MASATOSHI (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-1712242-B1 | METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT | HAGIWARA MASATOSHI (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-8816089-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | Hagiwara, Masatoshi (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8816089-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | Hagiwara, Masatoshi (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8816089-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | Hagiwara, Masatoshi (JP) | 2014-08-26 | — | — | US | disclosed |
| CN-101837125-B | Method of regulating phosphorylation of PTH protein and antiviral agents comprising SR protein activity regulator as the active ingredient | HAGIWARA MASATOSHI | 2014-02-26 | — | — | CN | disclosed |
| US-20100016359-A1 | METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY | MASATOSHI HAGIWARA | 2010-01-21 | — | — | US | disclosed |
| US-20100016359-A1 | METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY | MASATOSHI HAGIWARA | 2010-01-21 | — | — | US | disclosed |
| US-7569536-B2 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | Hagiwara, Masatoshi (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569536-B2 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | Hagiwara, Masatoshi (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569536-B2 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | Hagiwara, Masatoshi (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | HAGIWARA, MASATOSHI (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | HAGIWARA, MASATOSHI (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | HAGIWARA, MASATOSHI (JP) | 2007-06-14 | — | — | US | disclosed |
| CN-1921885-A | Method for controlling phosphorylation of SR protein and antiviral agent comprising SR protein activity controller as active ingredient | HAGIWARA MASATOSHI (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1712242-A1 | METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT | HAGIWARA, Masatoshi (JP) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | SRPK1, SARS1, SRPK3 | SRPK1 1/4885KDR 2410/4885SRPK2 4/4885 |
| US-20100016359-A1 | METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY | SRPK1, SRPK3, SRPK2 | SRPK1 1/4885KDR 4350/4885SRPK2 3/4885 |
| US-20210100781-A1 | TUMOR SUPPRESSION | TSG101, TP53, VHL | SRPK1 1293/4885KDR 3702/4885SRPK2 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.